20
Participants
Start Date
January 31, 2016
Primary Completion Date
August 31, 2019
Study Completion Date
October 31, 2019
amifampridine phosphate
Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
Placebo
A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
Johns Hopkins Pediatric Neurology, Baltimore
Ohio State University, Columbus
UCLA Department of Neurology, Los Angeles
Boston Children's Hospital, Boston
Lead Sponsor
Catalyst Pharmaceuticals, Inc.
INDUSTRY